Intelligent Antibody Discovery

Therapeutic monoclonal antibodies for medicine

Abeome is a privately-held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.

Read More »

Recent News

2016-09-22
Abeome Awarded $1.5M Grant for Technology and Therapeutic Antibody Development

Abeome Corporation announced today that it has received notification from the National Institute of Health – National Heart, Blood and Lung Institute of an award granting $1,482,472 over two years for the further development of proprietary monoclonal antibodies in Abeome’s portfolio.

2016-01-22
Abeome Honored by Georgia Bio for AbeoMouse™

Abeome Corporation announced today it has been named a Georgia Bio Innovation Award Winner.